Precision Medicine in Systemic Mastocytosis

Mastocytosis is a rare hematological neoplasm characterized by the proliferation of abnormal clonal mast cells (MCs) in different cutaneous and extracutaneous organs. Its diagnosis is based on well-defined major and minor criteria, including the pathognomonic dense infiltrate of MCs detected in bone marrow (BM), elevated serum tryptase level, abnormal MCs CD25 expression, and the identification of KIT D816V mutation. The World Health Organization (WHO) classification subdivides mastocytosis into a cutaneous form (CM) and five systemic variants (SM), namely indolent/smoldering (ISM/SSM) and advanced SM (AdvSM) including aggressive SM (ASM), SM associated to hematological neoplasms (SM-AHN), and mast cell leukemia (MCL). More than 80% of patients with SM carry a somatic point mutation of KIT at codon 816, which may be targeted by kinase inhibitors. The presence of additional somatic mutations detected by next generation sequencing analysis may impact prognosis and drive treatment strategy, which ranges from symptomatic drugs in indolent forms to kinase-inhibitors active on KIT. Allogeneic stem cell transplant (SCT) may be considered in selected SM cases. Here, we review the clinical, diagnostic, and therapeutic issues of SM, with special emphasis on the translational implications of SM genetics for a precision medicine approach in clinical practice.

[1]  J. Winkler,et al.  Health-related quality of life and influencing factors in adults with non-advanced mastocytosis - a cross-sectional study and qualitative approach. , 2021, The journal of allergy and clinical immunology. In practice.

[2]  A. Dorrance "Mast"ering drug discovery with iPSCs. , 2021, Blood.

[3]  R. Norman,et al.  The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. , 2021, Journal of clinical epidemiology.

[4]  M. Szczyrek,et al.  Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis , 2021, Journal of clinical medicine.

[5]  C. Kelly,et al.  The management of metastatic GIST: current standard and investigational therapeutics , 2021, Journal of Hematology & Oncology.

[6]  A. Orazi,et al.  Acute aleukemic mast cell leukemia: Report of a case and review of the literature , 2020, Leukemia research reports.

[7]  S. Rutella,et al.  Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. , 2020, Blood.

[8]  M. Mancini,et al.  Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy , 2020, International journal of molecular sciences.

[9]  S. Mustjoki,et al.  Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic Mastocytosis , 2020, bioRxiv.

[10]  T. George,et al.  New Developments in Diagnosis, Prognostication, and Treatment of Advanced Systemic Mastocytosis. , 2020, Blood.

[11]  C. Paul,et al.  Omalizumab in the treatment of adult patients with mastocytosis: A systematic review , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  D. Cella,et al.  The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index , 2020, Leukemia.

[13]  L. French,et al.  Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study) , 2020, Dermatology.

[14]  J. D. van der Walt,et al.  The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review , 2019, Pathobiology.

[15]  M. Vignetti,et al.  Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy , 2019, Leukemia.

[16]  M. Triggiani,et al.  Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches , 2019, International journal of molecular sciences.

[17]  Stacie L. Bulfer,et al.  Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. , 2019, Cancer cell.

[18]  J. Butterfield,et al.  Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. , 2019, The journal of allergy and clinical immunology. In practice.

[19]  L. Cro,et al.  A case report of systemic mastocytosis associated with multiple hematologic non–mast cell lineage diseases , 2019, Hematological oncology.

[20]  N. Cross,et al.  Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis. , 2019, Leukemia research.

[21]  A. Pardanani Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management , 2018, American journal of hematology.

[22]  E. Ranheim,et al.  Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  C. Bebbington,et al.  AK002, a Novel Humanized Monoclonal Antibody to Siglec-8, Inhibits Mast Cell Activity and Depletes Eosinophils in Ex Vivo Bone Marrow Tissue from Patients with Systemic Mastocytosis , 2018, Blood.

[24]  A. Tefferi,et al.  Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis , 2018, American journal of hematology.

[25]  P. Guglielmelli,et al.  Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. , 2018, Blood advances.

[26]  K. Roskin,et al.  Impact of somatic and germline mutations on the outcome of systemic mastocytosis. , 2018, Blood advances.

[27]  A. Tefferi,et al.  Practice‐relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm , 2018, American journal of hematology.

[28]  A. Tefferi,et al.  Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory‐specific incidence and prognostic impact among 348 informative cases , 2018, American journal of hematology.

[29]  S. Rosati,et al.  Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. , 2018, The Journal of allergy and clinical immunology.

[30]  S. Verstovsek,et al.  Patient Perceptions in Mast Cell Disorders. , 2018, Immunology and allergy clinics of North America.

[31]  Yvette N. Lamb,et al.  Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis , 2018, Drugs.

[32]  W. Hofmann,et al.  Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis , 2018, Genes, chromosomes & cancer.

[33]  J. Merker,et al.  Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial , 2018, Leukemia.

[34]  U. Borate,et al.  How we diagnose and treat systemic mastocytosis in adults , 2018, British journal of haematology.

[35]  A. Gardino,et al.  A precision therapy against cancers driven by KIT/PDGFRA mutations , 2017, Science Translational Medicine.

[36]  H. Kluin-Nelemans,et al.  Midostaurin: a magic bullet that blocks mast cell expansion and activation , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  F. Lo‐Coco,et al.  Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? , 2017, Blood.

[38]  I. Alvarez-Twose,et al.  Insights in Anaphylaxis and Clonal Mast Cell Disorders , 2017, Front. Immunol..

[39]  M. Mancini,et al.  SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis , 2017, Leukemia.

[40]  A. Tefferi,et al.  Next‐generation sequencing in systemic mastocytosis: Derivation of a mutation‐augmented clinical prognostic model for survival , 2016, American journal of hematology.

[41]  H. Deeg,et al.  Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  A. Órfão,et al.  Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature , 2016, Oncotarget.

[43]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[44]  W. Hofmann,et al.  Impact of centralized evaluation of bone marrow histology in systemic mastocytosis , 2016, European journal of clinical investigation.

[45]  C. Brooks,et al.  CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value , 2016, Leukemia.

[46]  G. Superti-Furga,et al.  Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth , 2016, Leukemia.

[47]  B. Grosbois,et al.  Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. , 2015, Blood.

[48]  Martin C. Müller,et al.  Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study , 2015, Journal of Cancer Research and Clinical Oncology.

[49]  T. Haferlach,et al.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event , 2015, Leukemia.

[50]  R. Gaillard,et al.  Neuropsychological features of adult mastocytosis. , 2014, Immunology and allergy clinics of North America.

[51]  C. Bindslev‐Jensen,et al.  Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis , 2014, American journal of hematology.

[52]  G. Cruse,et al.  Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. , 2014, Immunology and allergy clinics of North America.

[53]  Florent Langenfeld,et al.  Molecular defects in mastocytosis: KIT and beyond KIT. , 2014, Immunology and allergy clinics of North America.

[54]  K. Brockow Epidemiology, prognosis, and risk factors in mastocytosis. , 2014, Immunology and allergy clinics of North America.

[55]  G. Stefanzl,et al.  The pan‐Bcl‐2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells , 2014, Journal of leukocyte biology.

[56]  A. Kohlmann,et al.  Comprehensive mutational profiling in advanced systemic mastocytosis. , 2013, Blood.

[57]  H. Sokol,et al.  Gastrointestinal manifestations in mastocytosis: a study of 83 patients. , 2013, The Journal of allergy and clinical immunology.

[58]  Wei Yang,et al.  The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSα , 2013, Cell.

[59]  A. Órfão,et al.  International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. , 2013, Blood.

[60]  S. Verstovsek,et al.  Systemic mastocytosis with associated clonal hematological non‐mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components , 2013, American journal of hematology.

[61]  K. Sotlar,et al.  Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis , 2011, Modern Pathology.

[62]  J. Launay,et al.  Systemic mastocytosis and bone involvement in a cohort of 75 patients , 2010, Annals of the rheumatic diseases.

[63]  A. Tefferi,et al.  WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. , 2010, Blood.

[64]  A. Tefferi,et al.  Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosine , 2009, American journal of hematology.

[65]  A. Tefferi,et al.  Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. , 2009, Blood.

[66]  A. Tefferi,et al.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.

[67]  M. Dieguez,et al.  Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA) , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[68]  A. Órfão,et al.  Recent advances in the understanding of mastocytosis: the role of KIT mutations * , 2007, British journal of haematology.

[69]  W. Pickl,et al.  Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. , 2007, Blood.

[70]  D. Fabbro,et al.  PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. , 2006, Blood.

[71]  C. Chen,et al.  Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. , 2005, Blood.

[72]  A. Tefferi,et al.  Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. , 2004, Leukemia research.

[73]  K. Sotlar,et al.  Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge , 2004, Journal of Clinical Pathology.

[74]  A. Órfão,et al.  Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA) , 2004, Cytometry. Part B, Clinical cytometry.

[75]  B. Bain,et al.  Cytogenetic and Molecular Genetic Abnormalities in Systemic Mastocytosis , 2002, Acta Haematologica.

[76]  M. Tomonaga,et al.  Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-alpha. , 1998, Internal medicine.

[77]  W. Stremmel,et al.  Clinical stable systemic mastocytosis with interferon alpha 2b therapy. , 1997, Journal of internal medicine.

[78]  D. Metcalfe,et al.  Treatment of three patients with systemic mastocytosis with interferon alpha-2b. , 1996, Leukemia & lymphoma.

[79]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[80]  A. Torrelo,et al.  Urticaria Pigmentosa: A Review of 67 Pediatric Cases , 1994, Pediatric dermatology.

[81]  R. Spritz,et al.  Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. , 1992, Oncogene.

[82]  C. Decastro,et al.  Cloning and structural analysis of the human c-kit gene. , 1992, Oncogene.

[83]  D. Metcalfe,et al.  Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. , 1991, Journal of immunology.

[84]  R. Caplan The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. , 1963, Archives of dermatology.

[85]  T. Haferlach,et al.  Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis , 2016, Leukemia.

[86]  P. Valent Mast cell leukemia--a rare form of myeloid leukemia. , 2002, Wiener klinische Wochenschrift.